Vedanta Biosciences Stock

vedantabio.comHealthcare / BioTech & PharmaFounded: 2010Funding to Date: $211.6MM

Vedanta Biosciences, founded in 2017, is a clinical-stage company that has developed immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays that seek to enable physicians to access live bacteria drugs that are designed to treat autoimmune and inflammatory diseases easily. Vedanta Biosciences is headquartered in Cambridge, Massachusetts.

Register To Buy and Sell Shares

For more details on financing and valuation for Vedanta Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Vedanta Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Vedanta Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Bernat Olle Ph.D
Co-Founder, Chief Executive Officer & Board Member
Ruslan Medzhitov Ph.D
Chairman of Scientific Advisory Board & Scientific Co-Founder
Kevin Coveney
Senior Vice President, Finance
Dan Littman Ph.D
Scientific Co-Founder & Scientific Advisory Board Member
Bruce Roberts Ph.D
Chief Scientific Officer
Erik Spek Ph.D
Senior Vice President and Head, Legal Affairs & Intellectual Property
Lou Vaickus MD
Chief Medical Officer
Alexander Rudensky Ph.D
Scientific Co-Founder & Scientific Advisory Board Member
Daniel Couto
Chief Technical Officer
Kenya Honda Ph.D
Scientific Co-Founder & Scientific Advisory Board Member
Debra Winslow
Vice President, Program Management & Operations Planning
B. Brett Finlay Ph.D
Scientific Co-Founder & Scientific Advisory Board Member

Board Members

John LaMattina Ph.D
PureTech Health
Bharatt Chowrira Ph.D
PureTech Health
Bennett Shapiro MD
PureTech Health

Frequently Asked Questions About Vedanta Biosciences’ Stock

plusminus
Can you buy Vedanta Biosciences’ stock?
Vedanta Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Vedanta Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Vedanta Biosciences’ stock?
Yes, you can sell stock of a private company like Vedanta Biosciences. Forge can help you sell your Vedanta Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Vedanta Biosciences’ stock price?
Vedanta Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Vedanta Biosciences’ private market stock price with Forge Data.
plusminus
What is Vedanta Biosciences’ stock ticker symbol?
Vedanta Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Vedanta Biosciences raises funds to advance defined bacterial consortia therapies
Vedanta Biosciences has raised $106.5m in financing to advance a pipeline of defined bacterial consortia therapies. Co-led by new investors the AMR Action Fund and AXA IM Alts, the investment syndicate also included existing investors Reimagined Ventures, the Bill & Melinda Gates Foundation, Atlantic Neptune, Fiscus Ventures, PEAK6 and Skyviews Life Science.
Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consorti
Updated on: May 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.